MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors.
Eur J Endocrinol 2018 Feb 23. Epub 2018 Feb 23.
J Bertherat, Reference Center for rare adrenal diseases, Department of Endocrinology. Hôpitaux universitaires Paris-Centre, Assistance Publique - Hopitaux de Paris, Paris, France
Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis, the five-years overall survival being below 40%. However there is great variability of outcomes and we have now a better view of the heterogeneity of tumor aggressiveness. The extent of the disease at the time of diagnosis, best assayed by the European Network for the Study of Adrenal Tumors (ENSAT) staging score, is a major determinant of survival. Read More